BiotechTube
SphingoTec

SphingoTec

Hennigsdorf, Germany· Est.
sphingotec.eu
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $45M

Overview

SphingoTec is a privately-held diagnostics company specializing in the development and out-licensing of novel biomarkers for critical care. Its core strategy involves advancing proprietary biomarkers to the commercial stage and forming partnerships with established in-vitro diagnostic (IVD) companies for global distribution. The company's lead biomarkers, penKid for acute kidney injury assessment and bio-ADM for sepsis and endothelial dysfunction, target significant unmet needs in hospital emergency and intensive care settings. Recent clinical validation and a new product launch with partner Boditech Med demonstrate progress in translating its pipeline into clinical tools.

Acute Kidney InjurySepsisAcute Heart FailureCritical Care

Technology Platform

Proprietary biomarker discovery and validation platform focused on protein biomarkers for acute care, including penKid for real-time kidney function and bio-ADM for endothelial function.

Funding History

2
Total raised:$45M
Series B$30M
Series A$15M

Opportunities

Significant unmet diagnostic needs in critical care (sepsis, AKI) and a growing trend towards personalized medicine in hospitals create a large addressable market.
The successful validation of penKid in kidney transplantation opens a new, high-value clinical application beyond general critical care.
The out-licensing model allows for rapid global scale through established IVD partners without the need for heavy commercial infrastructure.

Risk Factors

Revenue is entirely dependent on the commercial execution of licensing partners, over which SphingoTec has limited control.
Widespread clinical adoption faces hurdles, including changing physician behavior and securing favorable reimbursement.
Competition from larger diagnostic companies and the need for continuous clinical validation pose ongoing scientific and commercial risks.

Competitive Landscape

SphingoTec competes in the crowded critical care diagnostics space, which includes large IVD conglomerates (e.g., Roche, Abbott) and other biomarker-focused firms. Its differentiation lies in the novel mechanism of its biomarkers (penKid, bio-ADM) and their specific performance advantages over legacy standards like serum creatinine. Competition is based on clinical evidence, partnership networks, and the ability to integrate into fast, point-of-care testing platforms used in ICUs.

More companies in Diagnostics & Precision Medicine →More companies in Germany →